CAPR News and Press, Capricor Therapeutics Inc. From 05/18/22

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Mar...

Capricor Therapeutics, Inc. (CAPR) Q1 2022 Earnings Conference Call May 10, 2022, 16:30 ET Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marban - Co-Founder, President, CEO & Director Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co. P...

Capricor Therapeutics press release (NASDAQ:CAPR): Q1 GAAP EPS of -$0.32. The company believes that based on the current operating plan and financial resources, the company expects that its available cash and cash equivalents of approximately $58.3M will be sufficient to cover anticipated exp...

-Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in the United States- -Upfront Payment of $30 Million Received in 1 st Quarter Strengthens Cash Position and Extends Cash Runway- ...

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results...

Shares of Capricor Therapeutics Inc. (NASDAQ:CAPR) traded today at $12.31, eclipsing its 52-week high. Approximately 144 million shares have changed hands today, as compared to an average 30-day volume of 272,000 shares. Capricor Therapeutics Inc. (NASDAQ:CAPR) is currently priced 0.4% a...

SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Ma...

Gainers: DatChat (DATS) +82%. Hycroft Mining Holding Corporation (HYMC) +66%. Plantronics (POLY) +50%. Kaixin Auto (KXIN) +31%. AMC Entertainment Holdings (AMC) +25%. TC Biopharm (TCBP) +23%. Creative Medical Technology (CELZ) +21%. Immunome (IMNM) +21%. Chi...

Gainers: ORIC Pharmaceuticals (ORIC) +19%. Aptorum (APM) +16%. STAAR Surgical (STAA) +16%. Creative Medical Technology (CELZ) +13%. Tempest Therapeutics (TPST) +11%. Losers: NeuroOne Medical Technologies (NMTC) -48%. Clever Leaves (CLVR) -26%. Capricor ...

A phase 2 trial of Capricor Therapeutics' (NASDAQ:CAPR) COVID-19 treatment CAP-1002 met its primary objective of safety. Although the study was not powered to determine efficacy, overall mortality was 20%. There were six deaths in the placebo group and five in the CAP-1002 group. Patients enr...